Cracking The Code On Complex Proteins: Your Development And Manufacturing Questions Answered

Bispecific antibodies, fusion proteins, and other complex molecules can expose development risks that standard monoclonal antibody workflows weren’t designed to address. Chain mispairing, linker clipping, aggregation, and expression challenges can affect everything from clone selection to purification and scale-up.

Reducing those risks starts early. Sequence and vector design should reflect the intended therapeutic application, while clone selection should balance titer with viability and product quality rather than productivity alone. Stability studies also need to represent real manufacturing conditions, including the complete duration of low-pH processing. Downstream, alternative affinity resins and tailored polishing strategies may be needed when conventional Protein A capture cannot adequately separate unwanted species.

Explore practical answers to common development and manufacturing questions for complex proteins, from cell line development through downstream purification.